{"id":"W2505446618","doi":"10.1016/j.bbmt.2016.07.007","title":"Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis","year":2016,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa","funders":"Office of Naval Research; Onyx Pharmaceuticals; Health Resources and Services Administration; Otsuka Pharmaceutical; Miltenyi Biotec; Incyte; Telomere Diagnostics; Sunesis; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Therakos; Sigma-Tau Pharmaceuticals; Chimerix; Medical College of Wisconsin; Takeda Oncology; University of Minnesota; Spectrum Pharmaceuticals; National Marrow Donor Program; St. Baldrick's Foundation; Genentech; Seattle Genetics; Pharmacyclics; Health Research; National Cancer Institute; Gilead Sciences; Leukemia and Lymphoma Society; Genzyme; Alexion Pharmaceuticals; Jazz Pharmaceuticals; Be The Match Foundation; Otsuka America Pharmaceutical; Amgen; National Institute of Allergy and Infectious Diseases; Roswell Park Cancer Institute; Fred Hutchinson Cancer Research Center; Celgene; Gamida Cell; WellPoint; Sanofi","keywords":"Medicine; Multiple myeloma; Internal medicine; Bortezomib; Confidence interval; Oncology; Fluorescence in situ hybridization; Transplantation; Chromosome; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002444538,0.000618322,0.001051908,0.001754312,0.000615215,0.001265319,0.001442742,0.0007399871,0.00501649],"category_scores_gemma":[0.004749873,0.0003128884,0.002759009,0.001532093,0.0004638519,0.00112258,0.001898746,0.00196205,0.000504846],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007227655,"about_ca_system_score_gemma":0.0008692667,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003653728,"about_ca_topic_score_gemma":0.003556353,"domain_scores_codex":[0.9982979,0.0003935667,0.0001448564,0.0003807739,0.0002373913,0.000545587],"domain_scores_gemma":[0.9966136,0.000742409,0.001351628,0.0003854304,0.0002208251,0.000686063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005177469,0.0001933939,0.9856089,0.00006560425,0.001780948,0.0001245292,0.0001557082,0.0002566889,0.0005596939,0.0002309613,0.0006290912,0.005217071],"study_design_scores_gemma":[0.0001149183,0.001027161,0.9958981,0.00001924748,0.0008091432,0.0002933581,0.0004377764,0.0006079546,0.000127689,0.0002033327,0.0004404361,0.00002098369],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977062,0.0003290206,0.0002346033,0.00008070328,0.0000187551,0.00002115424,0.0009068182,0.000008116875,0.0006945761],"genre_scores_gemma":[0.9983278,0.000100888,0.0001060829,0.00005598775,0.00003293554,0.00002743469,0.001082729,0.00001071504,0.0002554344],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00501649,"threshold_uncertainty_score":0.01678181,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009011483660965018,"score_gpt":0.2502191859858022,"score_spread":0.2412077023248372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}